Innovative therapeutics

Investors

NASDAQBMRN
FormDescriptionDateFormat
POS AMPost-effective amendment to an S-Type filingJul 22, 2004View HTMLDownload DOCDownload PDFDownload XLS
424B3Form of prospectus reflecting facts events constituting substantive change from last formJun 25, 2004View HTMLDownload DOCDownload PDFDownload XLS
S-3Simplified registration formJun 17, 2004View HTMLDownload DOCDownload PDFDownload XLS
424B3Form of prospectus reflecting facts events constituting substantive change from last formMar 19, 2004View HTMLDownload DOCDownload PDFDownload XLS
424B3Form of prospectus reflecting facts events constituting substantive change from last formMar 11, 2004View HTMLDownload DOCDownload PDFDownload XLS
424B3Form of prospectus reflecting facts events constituting substantive change from last formMar 4, 2004View HTMLDownload DOCDownload PDFDownload XLS
POS AMPost-effective amendment to an S-Type filingMar 3, 2004View HTMLDownload DOCDownload PDFDownload XLS
POS AMPost-effective amendment to an S-Type filingFeb 24, 2004View HTMLDownload DOCDownload PDFDownload XLS
424B3Form of prospectus reflecting facts events constituting substantive change from last formFeb 4, 2004View HTMLDownload DOCDownload PDFDownload XLS

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information